| Ytd | 118.59% | |
| 1y | -5.21% |
| Open | 14.26 | Prev Close | 14.72 | Low | 14.18 | High | 14.93 | Mkt Cap | 19.52M |
| Vol | 24.46K | Avg Vol | 82.55K | EPS | -11.66 | P/E | -1.28 | Forward P/E | -1.51 |
| Beta | -0.23 | Short Ratio | 2.64 | Inst. Own | 50.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 12.29 | 200-d Avg | 12.06 | 1yr Est | 7.65 |
PMN News
Total Revenue: $3.3 billion in Q2 2026, up 12% year-over-year.CF Revenue: Global CF revenue grew 11%
Company to host investor conference call and webcast at 4:30 p. m. ET. Cambridge, Massachusetts, Aug
Promis Neurosciences NASDAQ: PMN reported blinded six-month interim data from its Phase 1b PRECISE-A
Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se
ProMIS Neurosciences Inc. (NASDAQ:PMN) reported positive blinded six-month interim safety and biomar
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rate
Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess
Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN),
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 230.2% upside in the
Promis Neurosciences (PMN) might move higher on growing optimism about its earnings prospects, which
The average of price targets set by Wall Street analysts indicates a potential upside of 231.8% in P
BRISBANE, AUS, June 2, 2026 - (ACN Newswire) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX:
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive lic
CAMBRIDGE, Mass. , May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clini
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exer
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PM
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo